

11th European Stroke Organisation Conference

21–23 May 2025, Helsinki, Finland



Abstract Number: 29

Abstract Title: BEYOND ANTICOAGULATION: LIMITATIONS OF ORAL ANTICOAGULANTS IN PREVENTING STROKE RECURRENCE IN ATRIAL FIBRILLATION

Abstract Category: 05.00 - RISK FACTORS AND PREVENTION (PRIMARY AND SECONDARY) - 05.02 - SECONDARY PREVENTION

Preferred Presentation Type: Oral or Poster Presentation

Jessica Seetge^{*1}, Balázs Cséke¹, Zsófia Nozomi Karádi¹, Edit Bosnyák¹, László Szapáry¹

¹University of Pécs, Pécs, Hungary

Background and Aims: Despite the widespread use of oral anticoagulants (OACs), acute ischemic stroke (AIS) remains a significant risk for patients with atrial fibrillation (AF). The real-world effectiveness of OACs in preventing recurrent strokes, particularly following an initial stroke of cardioembolic origin, continues to be a major challenge. This study evaluates the efficacy of OACs in secondary stroke prevention and investigates the influence of anticoagulation type and quality on recurrence risk.

Methods: We analyzed data from 128 AF patients in the TINL STROKE-registry, admitted with cardioembolic stroke between 2023 and 2024. Patients were categorized by anticoagulation status at admission (OAC-users, n=89; anticoagulation-naïve, n=39). Recurrence rates were assessed using logistic regression models adjusted for confounders. Subgroup analyses explored the effects of anticoagulation type and quality.

Results: Recurrence rates were similar between OAC-treated and anticoagulation-naïve patients after adjusting for confounders (19.10% vs. 17.95%, p=0.870). Among anticoagulated patients, neither anticoagulation type nor quality alone significantly influenced recurrence risk. However, their interaction was statistically significant (p=0.049), suggesting that the effectiveness of anticoagulation in preventing strokes is strongly affected by treatment quality.

Conclusion: Although OACs are a cornerstone of stroke prevention in patients with AF, their efficacy in reducing recurrence depends on optimal management. These findings highlight that adequate anticoagulation, not just its use, is critical to minimize recurrence risk. To effectively prevent strokes in high-risk AF patients, future strategies must focus on standardized protocols, tailored monitoring, and individualized dosing regimens.

Disclosures: Jessica Seetge: nothing to disclose, Balázs Cséke: nothing to disclose, Zsófia Nozomi Karádi: nothing to disclose, Edit Bosnyák: nothing to disclose, László Szapáry: nothing to disclose

Travel Grant Application: No

Young Investigator Award Application: No